Author Topic: Emerging evidence on the selective use of AHSCT[stem cells] in MS  (Read 39 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8223
  • MS diagnosed 1980
  • Location: Pacific Northwest

Looking at the "optimal profile" for people who might benefit from AHSCT (autologous hematopoietic stem cell transplantation), I'd say that the use of it will be very selective.


Quote
RRMS or progressive MS for a short timeRelapses in the previous year, indicating recent clinical inflammatory activityRecent inflammatory activity, as identified by magnetic resonance imagingAge less than 45 yearsDuration of disease of 10 years or lessDisability designated as low to moderateFailure of no more than 2 prior disease-modifying therapiesNo clinically significant comorbiditiesCognitive ability to agree to and adhere to recommended care, especially in immunocompromised phases.


"Emerging evidence on the selective use of AHSCT in MS"--from MedPage Today, October 29, 2018:


https://www.medpagetoday.com/resource-centers/progress-multiple-sclerosis-detection-management/emerging-evidence-selective-use-ahsct-ms/2268?xid=nl_mpt_DHE_2018-10-29&eun=g345846d0r&pos=111111111&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-10-29&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
2 Replies
84 Views
Last post March 17, 2017, 03:50:00 pm
by agate
0 Replies
73 Views
Last post March 16, 2017, 03:48:27 pm
by agate
0 Replies
29 Views
Last post September 08, 2018, 04:48:40 pm
by agate
0 Replies
12 Views
Last post August 02, 2019, 02:55:41 pm
by agate
0 Replies
18 Views
Last post August 15, 2019, 09:21:51 pm
by agate